C12N2501/33

CELLS GENETICALLY MODIFIED TO COMPRISE PANCREATIC ISLET GLUCOKINASE AND USES THEREOF
20180010104 · 2018-01-11 ·

The present invention relates generally to a population of cells genetically modified to produce insulin in a glucose responsive manner and uses thereof. More particularly, the present invention relates to a population of cells genetically modified to produce insulin in response to physiologically relevant levels of glucose and uses thereof. The cells of the present invention are useful in a wide variety of applications, in particular in the context of therapeutic and prophylactic regimes directed to the treatment of diabetes and/or the amelioration of symptoms associated with diabetes, based on the transplantation of the cells of the present invention into mammals requiring treatment. Also facilitated is the design of in vitro based screening systems for testing the therapeutic effectiveness and/or toxicity of potential adjunctive treatment regimes.

METHODS, CULTURE MEDIAS AND DEVICES FOR GENERATING EMBRYOS IN VITRO FROM STEM CELLS

Disclosed herein include methods and compositions for culture medias for in vitro culture of synthetic embryos from mammalian pluripotent stem cells and extra-embryonic stem cells. The methods and compositions described herein can generate synthetic embryos at different developmental stage reaching early organogenesis and beyond. Disclosed herein also include an embryo culturing system and methods of using same.

NEW USE OF REGEND001 CELL AUTOLOGOUS DELIVERABLE PREPARATION IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
20230000926 · 2023-01-05 ·

The present invention provides a REGEND001 cell autologous deliverable preparation, and a use thereof for improving the pulmonary function of a patient suffering from idiopathic pulmonary fibrosis. The preparation is prepared by collection, in vitro isolation and culture and amplification of the patient's autologous bronchial basal cells.

Method for manufacturing body substitutes by additive deposition

The invention relates to a method for manufacturing a bio-ink by additive deposition, which comprises supplying: a first solution including between 5 and 40 wt. % gelatin; a second solution including between 15 and 35.wt. % alginate; a third solution including between 1 and 15 wt. % fibrinogen, and optionally living cells in suspension; and creating a mixture including: around 35 to 65 vol. % of the first solution; around 15 to 35 vol. % of the second solution; and around 15 to 35 vol. % of the third solution, said proportions being selected so that they add up to 100%. Said bio-ink allows the additive deposition of objects that can be polymerised by means of a solution including calcium ions and thrombin. Said objects can be incubated and can be used as a substitute for body tissue, for example (with added fibroblasts) as skin substitute.

Expansion and maintenance of adult primary human hepatocytes in culture

Methods for derivation, culture, and maturation of small hepatic progenitor cells are described.

APPLICATIONS OF BUTYLIDENEPHTHALIDE

Applications of butylidenephthalide (BP), comprising the use of BP in providing a kit for promoting differentiation of stem cells into brown adipose cells, and the use of BP in preparing a medicament, wherein the medicament is used for inhibiting the accumulation of white adipose cells, promoting the conversion of white adipose cells into brown adipose cells, inhibiting weight gain and/or reducing the content of triglycerides, glucose, and total cholesterol in blood.

METHOD FOR PREPARING MESENCHYMAL STEM CELLS HAVING IMPROVED VIABILITY THROUGH ANTI-CANCER VIRUS INTRODUCTION
20230016479 · 2023-01-19 ·

The present invention relates to a method for preparing oncolytic virus-containing mesenchymal stem cells having improved cell viability, a method for storing the oncolytic virus-containing stem cells produced by the method, and a cell therapeutic agent for cancer treatment containing the oncolytic virus-containing stem cells produced by the method. More particularly, an oncolytic virus is introduced into mesenchymal stem cells, followed by treatment with aspirin, so that the infection efficiency of the oncolytic virus may be increased, the replication time of the virus may be prolonged, and lysis of the stem cells by the virus may be prevented, thereby improving the viability and survival period of the stem cells and preparing anticancer stem cells having excellent activity. The anticancer stem cell therapeutic agent produced in this way is maintained at high viability during cold storage due to aspirin treatment, and thus is very useful medically and industrially.

METHOD FOR DIRECT TRANSDIFFERENTIATION OF SOMATIC CELL

A method of direct transdifferentiation of somatic cells into other somatic cells may be convenient and still have good reproducibility, excellent production efficiency, and short performed time. Methods for direct transdifferentiation of somatic cells into other somatic cells may include: (a) introducing a GLIS family gene, a mutated GLIS family gene or a gene product thereof into somatic cells; and (b) culturing the gene-introduced somatic cells in a culture medium containing a component that induces differentiation of the somatic cells or precursor cells of the somatic cells into other somatic cells.

METHOD FOR MASS PROLIFERATION OF URINE-DERIVED PLURIPOTENT CELLS
20230212521 · 2023-07-06 · ·

A method for the mass proliferation of urine-derived multipotent cells and a medium composition for the mass proliferation of urine-derived multipotent cells according to the present invention can be used to massively proliferate urine cells by efficiently isolating the same even from urine that has been left alone for a long period of time, and can be used to produce multipotent cells having characteristics of epithelial cells, mesenchymal cells, and stem cells.

Use of matrix cells for preparing a micro hair follicle
11530384 · 2022-12-20 · ·

The invention relates to the use of matrix cells for obtaining a micro hair follicle and to the use thereof for evaluating the effect of cosmetic, pharmaceutical or dermatological products and also for the prophylactic or therapeutic treatment of a state of reduced pilosity.